Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSS Trial
NCT07579429Phase 2Recruiting
- Sponsor
- University of Colorado Denver
- Start
- May 2026
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nicotinamide riboside in myelodysplastic syndrome (MDS), clonal cytopenia of undetermined significance (CCUS), sponsored by University of Colorado Denver. Started May 2026; status: recruiting.
02
Drugs
nicotinamide riboside
03
Conditions
myelodysplastic syndrome (MDS)clonal cytopenia of undetermined significance (CCUS)
Beyond the preview
Go deeper on NCT07579429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07579429.